Medicenna: Solving The Impossible In Glioblastoma With Medidata AI Synthetic Control Arm

In this video, Dr. Fahar Merchant, President and CEO of Medicenna, discusses Medicenna’s MDNA55-05 clinical trial; a single-arm, open-label, multicenter study that offers a promising opportunity to improve outcomes for recurrent glioblastoma (rGBM), one of the most aggressive forms of cancer. The trial represents the very first design of a Phase 3 registration trial where the majority of the patients would come from a synthetic control arm.